Literature DB >> 17387480

[Systemic immunosuppressives after penetrating keratoplasty].

A Reis1, F Birnbaum, T Reinhard.   

Abstract

Immunologic rejection is the main cause of corneal graft failure. If corneal transplantation is performed in a high-risk situation without the use of systemic immunosuppression, corneal graft failure has to be expected in over 50% of patients within the first postoperative year. The clonal expansion of graft-specific lymphocytes occurs in lymphoid tissues. As topical steroids do not reach the secondary lymphoid organs, and even systemic steroids do not interfere sufficiently with the clonal expansion of activated T cells, it is essential to administer systemic immunosuppressives in order to achieve clear graft survival. As corneal transplantation is not a life-saving procedure, the profile of side-effects is a central issue when choosing an immunosuppressive medication.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17387480     DOI: 10.1007/s00347-007-1517-x

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  48 in total

1.  Synergism of RAD and cyclosporin A in prevention of acute rat corneal allograft rejection.

Authors:  Alexander Reis; Mosaad Megahed; Thomas Reinhard; Erhard Godehardt; Christian Braunstein; Rainer Sundmacher
Journal:  Cornea       Date:  2002-01       Impact factor: 2.651

2.  Topical cyclosporin A in the treatment of corneal graft reaction.

Authors:  F Hoffmann; M Wiederholt
Journal:  Cornea       Date:  1986       Impact factor: 2.651

3.  An animal model for corneal graft rejection in high-risk keratoplasty.

Authors:  J C Hill; R Maske
Journal:  Transplantation       Date:  1988-07       Impact factor: 4.939

4.  FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics.

Authors:  T Kino; H Hatanaka; M Hashimoto; M Nishiyama; T Goto; M Okuhara; M Kohsaka; H Aoki; H Imanaka
Journal:  J Antibiot (Tokyo)       Date:  1987-09       Impact factor: 2.649

5.  The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients.

Authors:  M G Murgia; S Jordan; B D Kahan
Journal:  Kidney Int       Date:  1996-01       Impact factor: 10.612

6.  A randomized, double-blind, placebo-controlled study to determine safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients.

Authors:  C Brattström; G Tydén; J Säwe; G Herlenius; K Claesson; C G Groth
Journal:  Transplant Proc       Date:  1996-04       Impact factor: 1.066

Review 7.  Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection.

Authors:  W D Simmons; S C Rayhill; H W Sollinger
Journal:  Drug Saf       Date:  1997-08       Impact factor: 5.606

8.  FK-506 delays corneal graft rejection in a model of corneal xenotransplantation.

Authors:  U Benelli; A Lepri; M Del Tacca; M Nardi
Journal:  J Ocul Pharmacol Ther       Date:  1996       Impact factor: 2.671

9.  Suppression of corneal graft rejection by subconjunctival injection of FK-506 in a rat model of penetrating keratoplasty.

Authors:  A Minamoto; H Sakata; K Okada; M Fujihara
Journal:  Jpn J Ophthalmol       Date:  1995       Impact factor: 2.447

10.  Effect of mycophenolate mofetil, cyclosporin A, and both in combination in a murine corneal graft rejection model.

Authors:  A Reis; T Reinhard; R Sundmacher; C Braunstein; E Godehardt
Journal:  Br J Ophthalmol       Date:  1998-06       Impact factor: 4.638

View more
  7 in total

Review 1.  [Old immune system- new information? Importance of mononuclear phagocytes in corneal allograft rejection].

Authors:  T Lapp; D Reinhold; P Maier; T Reinhard
Journal:  Ophthalmologe       Date:  2012-09       Impact factor: 1.059

2.  [Intracameral application of corticosteroids for treating severe endothelial rejection after penetrating keratoplasty].

Authors:  F Birnbaum; P Maier; T Reinhard
Journal:  Ophthalmologe       Date:  2007-09       Impact factor: 1.059

Review 3.  [Immunosuppressives to prevent rejection reactions after allogeneic corneal transplantation].

Authors:  T Lapp; P Maier; F Birnbaum; G Schlunck; T Reinhard
Journal:  Ophthalmologe       Date:  2014-03       Impact factor: 1.059

4.  Long-term safety outcome of systemic immunosuppression in pig-to-nonhuman primate corneal xenotransplantation.

Authors:  Se Hyun Choi; Chang Ho Yoon; Hyun Ju Lee; Hong Pyo Kim; Jong Min Kim; Jeong-Hwan Che; Kyoung Min Roh; Hyuk Jin Choi; Jiyeon Kim; Eung Soo Hwang; Chung-Gyu Park; Mee Kum Kim
Journal:  Xenotransplantation       Date:  2018-07       Impact factor: 3.907

5.  Topical pimecrolimus does not prolong clear graft survival in a rat keratoplasty model.

Authors:  Florian Birnbaum; Johannes Schwartzkopff; Christoph Scholz; Thomas Reinhard
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-08-21       Impact factor: 3.117

6.  Outcome of penetrating keratoplasty in corneal ulcer: a single-center experience.

Authors:  Mohammad Reza Sedghipour; Rana Sorkhabi; Abdollah Shenasi; Hassan Dehghan
Journal:  Clin Ophthalmol       Date:  2011-09-06

7.  Functional antigen matching in corneal transplantation: matching for the HLA-A, -B and -DRB1 antigens (FANCY) - study protocol.

Authors:  Daniel Böhringer; Gabriele Ihorst; Birgit Grotejohann; Julia Maurer; Eric Spierings; Thomas Reinhard
Journal:  BMC Ophthalmol       Date:  2014-12-13       Impact factor: 2.209

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.